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Acetyl CoA-dependent arylamine N-acetyltransferase (EC 2.3.1.5) is the target of a genetic polymorphism in the meta- 
bolism of drugs and carcinogens. N-Acetyltransferase was purified IOOO-fold from cytosol of human liver and its identity 
was verified by amino acid sequence homology of two of its tryptic peptides with published rabbit and chicken N-acetyl- 
transferase sequences. Enzyme activity correlated with the presence of two proteins, NAT-I and NAT-2, with indistin- 
guishable molecular masses (31 kDa). NAT-I and NAT-2 could be separated by anion-exchange chromatography and 
were functionally distinguished by their different apparent affinities for the acceptor amine sulfamethazine (SMZ). Anti- 
bodies raised against NAT-I were able to recognize both isozymes on Western blots. 
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1. INTRODUCTION 
One of the first genetic polymorphisms found to 
affect the biotransformation of drugs and 
xenobiotics in man was that leading to interin- 
dividual variation in the N-acetylation of primary 
arylamine and hydrazine substrates [ 1,2], catalysed 
by the acetyl-CoA-dependent arylamine N- 
acetyltransferase (EC 2.3.1.5) present in highest 
levels in liver cytosol [3]. Although the clinical and 
toxicological consequences of the human acetyla- 
tion polymorphism have been studied in con- 
siderable detail [4,5], as yet only limited data are 
available concerning its molecular basis. The pre- 
sent understanding of the mechanisms underlying 
polymorphic drug acetylation in human popula- 
tions therefore relies largely upon extrapolation 
from animal model systems [5,6]. 
In the rabbit, a genetically determined polymor- 
phism in liver N-acetyltransferase activity closely 
parallels that seen in man. Kinetic and im- 
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munological experiments [7,8] suggest he presence 
of a structurally altered N-acetyltransferase pro- 
tein in slow acetylator rabbits with altered kinetic 
properties. A 33 kDa protein with N- 
acetyltransferase activity has recently been purified 
to homogeneity from liver of rapid acetylator rab- 
bits [9]. However, it has not yet been possible to 
purify and to compare the proposed variant form 
from slow acetylator liver. An acetylation 
polymorphism is also observed in hamster popula- 
tions, but the pattern of substrates affected by the 
genetic defect is essentially the inverse of that 
observed in man and rabbit: arylamines which are 
able to discriminate rapid and slow acetylators in 
the latter two species are unable to do so in 
hamsters. Hamster liver contains two distinct N- 
acetyltransferase nzymes, and the evidence so far 
suggests that variation in the liver content of only 
one of these forms is responsible for the observed 
in vivo phenotypic variations [lo]. Purification of 
these genetically variable and constant isozymes 
has not yet been reported, 
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HPLC assay for partial purification and 
characterization of arylamine N-acetyltransferase 
from cytosol of human liver. 
2. MATERIALS AND METHODS 
2.1. N-Acetyltransferase assay 
Incubation conditions were essentially as described [ 1 I], us- 
ing a final acetyl-CoA cofactor concentration of 1OOpM. For 
enzyme purification, sulfamethazine (SMZ) was used as accep- 
tor amine at 200 pM. The HPLC assay measuring AcSMZ for- 
mation was developed as a modification of a published 
procedure [ 121. Reactions (90 ~1 volume) were stopped by addi- 
tion of 10 pl of 15% HCl04, samples were mixed and centrifug- 
ed to precipitate protein and tubes were loaded directly into an 
autosampler (Gilson model 23 1) programmed to inject 50 pl of 
each supernatant onto a reversed-phase column packed with 
Nucleosil S-Cl8 (Machery-Nagel, FRG). Samples were eluted at 
2.0 ml/min with a mobile phase consisting of 20 mM NaCl04 
(pH 2.5) and acetonitrile (88.5: 11.5, w/w), and compounds 
were detected by UV absorbance at 254 nm. Under these condi- 
tions the retention times of SMZ and its metabolite AcSMZ 
were 3.0 and 4.2 min. respectively. AcSMZ for assay calibra- 
tion was synthesized according to [13] and its purity was 
verified by HPLC. The sensitivity of the assay (injection 
volume, 50 pl; signal-to-noise ratio, 3 : 1) for the measurement 
of AcSMZ was 8 pmol, representing detection of 10% conver- 
sion of 1 FM SMZ or 0.01% conversion of 1 mM SMZ. Coeffi- 
cients of variation (n = 3) averaged 1.4% for quantities of 
AcSMZ between 0.08 and 1.5 nmol. 
2.2. Enzyme purification 
Procedures were adapted from those reported for rabbit [9] 
and pigeon [14] liver N-acetyltransferases. Human liver 
[lOt-250 g, obtained from kidney transplant donors (KDL) 
and stored at -80°C after shock-freezing in liquid Nz] was 
thawed and homogenized in TEDK buffer (10 mM 
triethanolamine-HCl, 1 mM EDTA, 1 mM DTT, 50 mM KCl, 
pH 7.0) and cytosol was prepared by differential centrifugation. 
Solid ammonium sulfate was added to 55010 saturation and the 
precipitated protein was redissolved and dialysed vs TEDK. The 
pH of the dialysate was adjusted to 5.5 with HCI, the sample 
was centrifuged, the precipitated protein was discarded and the 
supernatant was readjusted to pH 7.0 for application to a col- 
umn (5 x 30 cm) of DEAE-Sephacel (Pharmacia) equilibrated 
with TEDK. The column was washed and then developed with 
a linear 2 1 gradient from 50 to 200 mM KC1 in the same buffer, 
active fractions (10 ml) pooled, concentrated by ultrafiltration 
and applied to a Sephacryl S-200 (Pharmacia) column (2.5 x 
70 cm). Fractions (3 ml) with activity were pooled and concen- 
trated, then passed through a Sephadex G-25 column 
equilibrated with TDKP buffer (TEDK without EDTA, and 
containing 10 mM phosphate) and applied to a hydroxyapatite 
column (Bio-Gel HTP, 1.6 x 15 cm) equilibrated with TDKP. 
Enzyme activity was eluted with a linear gradient from 10 to 
300 mM phosphate in the same buffer, active fractions (2 ml) 
concentrated by ultrafiltration, dialysed vs TED buffer and ap- 
plied to a column (1 x 6 cm) of CoA-Sepharose (Pharmacia) 
equilibrated with TED buffer. The column was developed with 
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a linear gradient from 0 to 50 mM KC1 in the same buffer. Frac- 
tions (1 ml) with activity were pooled, concentrated by 
ultrafiltration and either used directly for preparative SDS- 
PAGE [15] and analytical-scale chromatographic procedures, 
or stabilized with glycerol (to 10%) and bovine serum albumin 
(2 mg/ml) for activity measurements. 
2.3. Amino acid sequencing of N-acetyltransferase tryptic 
peptides 
The first peak of N-acetyltransferase activity eluting from a 
DEAE-Sephacel anion-exchange column, designated NAT-l 
(fig.1) was pooled separately and further purified as described 
above. An aliquot of the NAT-l activity pool was subjected to 
preparative SDS-PAGE (10% gel), protein in the excised 
31 kDa band was digested with trypsin and peptides were 
separated by HPLC [16]. Selected peptides were sequenced us- 
ing a gas-phase sequencer (model 470A. Applied Biosystems) 
and the phenylthiohydantoin derivatives determined using a 
reversed-phase HPLC system as in [17]. 
2.4. Antibody production and immunoreaction on Western 
blots 
Another portion of the NAT-l activity pool was run on a se- 
cond SDS gel, excised 3 1 kDa gel band pieces being homogeniz- 
ed in complete Freund’s adjuvant and injected directly into a 
rabbit. Further boosts with identical antigen preparations 
followed 4 and 6 weeks later. Electrophoretic transfer of SDS- 
PAGE-separated proteins onto nitrocellulose [18], im- 
munoreaction with rabbit antiserum and detection by 
autoradiography using “‘I-protein A were performed using 
standard protocols. 
2.5. Enzyme kinetics 
Velocities of AcSMZ production were determined for a range 
of SMZ concentrations from 1 ,xM to 1 mM, with incubation 
times and enzyme dilutions adjusted to ensure no more than 
15% substrate conversion. Kinetic parameters (K, and I’,,,,,) 
were determined by linear regression after transformation of 
the data according to Hofstee [19]. Protein was assayed with a 
dye-binding method [20]. 
3. RESULTS AND DISCUSSION 
A full understanding of the underlying 
molecular causes of genetic polymorphisms in 
drug-metabolizing enzymes requires the direct 
study of the human liver proteins taking part in the 
affected reactions [21,22]. Using a sensitive new 
HPLC assay, we undertook the purification of N- 
acetyltransferase with the goal of developing an- 
tibodies and DNA probes that could be used to 
compare genetically rapid and slow acetylator in- 
dividuals with respect o enzyme content and func- 
tion, levels of gene transcription and ultimately the 
exact nature of the gene mutations involved. 
A total of 6 preparative-scale purifications were 
performed using two human livers (KDL 21, KDL 
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23) chosen from a pool of 35 livers on the basis of 
high cytosolic N-acetyltransferase activity. 
Chromatographic procedures were used in a varie- 
ty of sequences, resulting in between 830 and 
2400-fold purification with recovery of 0.3-48% 
of the original cytosolic activity. Table 1 sum- 
marizes a typical purification sequence. N- 
Acetyltransferase was a very minor component 
even of high-activity liver cytosol: after greater 
than lOOO-fold purification, analytical SDS-PAGE 
showed that such preparations were still no more 
than about 10% pure. Moreover, after reaching 
this stage of purity, enzyme activity was rapidly 
lost unless high concentrations of glycerol and 
albumin were added for stabilization. 
An important observation from the enzyme 
purifications was the presence of two separate 
peaks of enzyme activity, which we designated 
NAT-l and NAT-2, after anion-exchange 
chromatography on DEAE-Sephacel (fig. 1). The 
same two activity peaks were seen in a total of 12 
independent anion-exchange column runs using ex- 
tracts from four different human livers, and also 
when column fractions were analysed for enzyme 
activity using p-aminobenzoic acid, p- 
aminosalicylic acid, 5aminosalicylic acid, pro- 
cainamide, sulfamerazine, sulfadiazine or 
sulfapyridine as acceptor amine substrate. Omis- 
sion of the ammonium sulfate or pH-shift 
precipitation steps did not alter this pattern, and 
when either peak was collected separately and 
reapplied to a second anion-exchange column it 
eluted again as a single peak in the expected posi- 
tion. During purifications where NAT-l and 
NAT-2 were separated at the DEAE-Sephacel step, 
the activities showed identical behavior on subse- 
quent size-exclusion columns and only partial 
resolution by chromatography on hydroxyapatite 
columns. Chromatofocussing of the separated ac- 
tivities [pH gradient 7-4 with Polybuffer (Phar- 
macia)] gave apparent pl values of 4.80 and 4.75 
for NAT-l and NAT-2, respectively, with very low 
recovery of both activities. 
The low liver content and instability of native N- 
acetyltransferase prevented its complete purifica- 
tion in reasonable quantity for physicochemical 
and functional analysis and for development of an- 
tibody probes recognizing the enzymatically active 
protein. However, analytical SDS-PAGE of col- 
umn eluate fractions during purification of NAT-l 
showed that the silver-staining intensity of a pro- 
tein band at 31 kDa correlated with N- 
acetyltransferase activity through all purification 
steps, regardless of their order. The 31 kDa pro- 
tein was therefore purified in its denatured form by 
preparative SDS-PAGE and subjected to tryptic 
digestion and peptide microsequencing. Two tryp- 
tic peptides (P55, P50) showed 76 and 67% 
homology, respectively, with the amino acid se- 
quences of tryptic peptides from purified rabbit 
Table 1 
Purification of N-acetyltransferase from human liver 
Purification step Protein 
mg total mg/ml 
Activity Purification Recovery 
(-fold) (Q) 
mU/mg U total 
105000 x supernatant g 3921 11.6 0.582 2282 1.0 100 
Ammonium sulfate 
precipitation 2684 22.0 0.853 2289 1.5 100 
pH-shift precipitation 2079 18.0 1.01 2100 1.7 92 
DEAE-Sephacel anion 
exchange 221 35.6 11.1 2453 19.1 107 
Sephacryl S-200 gel 
filtration 20.5 0.5 70.3 1441 121 63 
Hydroxyapatite 3.7 3.1 427 1580 734 69 
CoA-Sepharose 0.77 0.35 551 424 947 19 
Purification was from 100 g human liver KDL 21. In the purification above, the two peaks of activity 
eluting from the DEAE-Sephacel column (fig.1) were pooled together for the subsequent column 
procedures 
205 
Volume 244, number 1 FEBS LETTERS February 1989 
0 200 400 
FRACTION NUMBER 
Fig. 1. DEAE-Sephacel anion-exchange chromatography of N- 
acetyltransferase activity in extracts from human liver cytosol. 
liver N-acetyltransferase [9] (fig.2). The latter were 
verified by comparison with the deduced sequence 
arising from a full-length rabbit liver N- 
acetyltransferase cDNA which we have recently 
isolated and functionally expressed in a COS-1 cell 
transient expression system (submitted). Signifi- 
cant homology was also observed with regions of 
the deduced amino acid sequence from a cDNA en- 
coding chicken liver N-acetyltransferase [23]. 
Thus, the identity of the SDS-PAGE-purified 
31 kDa protein as a human N-acetyltransferase 
was established. Attempts at amino-terminal se- 
quencing of the intact protein using a glass fiber 
blotting method [24] were unsuccessful, suggesting 
N-terminal blockage of human N-acetyltransferase 
as has already been observed for the rabbit [9] and 
chicken [25] proteins. 
0 Peak fractions of NAT-l and NAT-2 from 
human liver KDL 21 differed in their affinity for 
SMZ at a fixed (100 PM) concentration of acetyl- 
CoA (fig.3). NAT-l had a lower apparent affinity 
(Km = 118 ,uM) than NAT-2 (62 ,uM) in the liver 
tested. When the acetyl-CoA cofactor concentra- 
tion was varied at a constant (100 PM) level of ac- 
ceptor amine, K, values for cofactor binding were 
80 and 130 PM, suggesting that the functional dif- 
ference between NAT-l and NAT-2 may relate to 
the efficiency of formation of the covalent acetyl- 
enzyme complex in the first half-reaction [26]. 
A rabbit antiserum raised against the SDS- 
denatured NAT-l 31 kDa antigen recognized 
bands on Western blots from both NAT-l and 
NAT-2 anion-exchange peaks at an identical 
molecular mass (fig.3). The serum also specifically 
Rabbit NKLDLEMLTDIFQHQ 
n”l?la” NKLDLETLTDI/LETIQ 
chicten K D AID L mT L T m I F Cl HIH 
Fig.2. Comparison of tryptic peptide sequences from human 
NAT-l with rabbit and chicken liver N-acetyltransferases. 
Numbers in parentheses identify rabbit peptides according to 
[9] and chicken sequences taken from the deduced amino acid 
sequence reported in [23]. 
reacted with purified rabbit liver N- 
acetyltransferase at a higher molecular mass 
(33 kDa) on Western blots (not shown). These 
results verify the antigenic relatedness of these 
three proteins and the higher molecular mass of the 
rabbit enzyme [9]. The antiserum was unable to in- 
hibit or immunoprecipitate native N- 
acetyltransferase activity in either species. 
Taken together, our observations suggest that 
arylamine N-acetyltransferase activity in human 
liver cytosol is associated with the presence of two 
proteins with very similar but distinct structural 
and functional properties. We do not know 




Fig.3. Kinetic analysis (Eadie-Hofstee plot) of N- 
acetyltransferase activities in NAT-l and NAT-2 anion- 
exchange chromatography peaks using SMZ as acceptor 
substrate. Inset: immunoreaction on Western blots of NAT-I 
and NAT-2 activity pools using a rabbit antiserum raised 
against SDS-denatured NAT-l isolated from human liver. 
Apparent immunoreactivity at 53 kDa is due to direct binding 
of ‘251-protein A to human IgG heavy chains present in the 
impure enzyme preparations. 
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genes or whether one arises from the other via 
post-transcriptional or post-translational process- 
ing, but we have reason to believe that the two pro- 
teins are not allelic variants at a single 
heterozygous gene locus. We have recently isolated 
N-acetyltransferase clones from a hEMBL3 
genomic library constructed using DNA obtained 
from a defined heterozygous rapid acetylator in- 
dividual. Ultimately, definitive answers to the 
above questions will arise from a direct 
characterization of the gene(s) involved. These 
studies are currently in progress. 
Of equal importance, in light of the differing 
models proposed from the results of the animal 
studies discussed above, is the question of how the 
quantity and/or activity of these two proteins 
relates to the functional expression of the rapid 
and slow acetylation phenotypes observed in 
human populations. The results of kinetic and im- 
munological experiments designed to address this 
issue will be presented elsewhere. 
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